Figure 2:

Loss of p16 enhances sensitivity of IDH-mutant glioma lines to CDK4/6 inhibition. A. Western blot of parental and CDKN2A knockout MGG152 lines showing loss of p16 expression and changes in Rb phosphorylation in the presence of abemaciclib treatment (300 nM). Cyclophilin B is used as a loading control. B. Cell viability assay of MGG152 lines after exposure to abemaciclib at the indicated concentrations for 5 days. C. Cell viability following abemaciclib treatment at 100 nM. n = 3 for each concentration, bars ± SEM. Data are representative of three biological replicates. **** p < 0.0001.